Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.

ABSTRACT:

Context

Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis.

Objective

The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover.

Design and setting

This was an international, multicenter, randomized, double-blind trial.

Participants

A total of 643 postmenopausal women with osteoporosis previously treated with oral bisphosphonates participated in the study.

Interventions

Subjects were randomized 1:1 to sc denosumab 60 mg every 6 months plus iv placebo once or ZOL 5 mg iv once plus sc placebo every 6 months for 12 months.

Main outcome measures

Changes in BMD and bone turnover markers were measured.

Re

SUBMITTER: Miller PD 

PROVIDER: S-EPMC4971333 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature